Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14833539 | 0.82 | HDAC6 (0.52) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL6449991 | 0.78 | USP2 (0.41) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL15331067 | 0.74 | HDAC6 (0.56) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL31248989 | 0.74 | SMN1; SMN2 (0.65) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL3746825 | 0.74 | SMN1; SMN2 (0.65) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL17933571 | 0.73 | HDAC6 (0.72) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL6866036 | 0.73 | SMN1; SMN2 (0.53) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL14685205 | 0.73 | SMN1; SMN2 (0.68) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL5610013 | 0.73 | SMN1; SMN2 (0.68) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT | |
| SCHEMBL4497713 | 0.72 | HDAC6 (0.61) | HDAC6SMN1; SMN2USP2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | ABBVIE INC. (US) | 2014-07-10 | — | — | US | disclosed |
| US-8653141-B2 | HIV protease inhibiting compounds | ABBVIE INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2264032-B1 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBVIE INC (US) | 2013-08-07 | — | — | EP | disclosed |
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | US | disclosed |
| EP-2216334-B1 | HIV protease inhibiting sulfonamides | ABBOTT LAB (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-1697348-B1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 2011-12-28 | — | — | EP | disclosed |
| EP-2266971-A2 | Hiv protease inhibiting compounds | Abbott Laboratories (US) | 2010-12-29 | — | — | EP | disclosed |
| EP-2264032-A2 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-12-22 | — | — | EP | disclosed |
| EP-2216334-A1 | Hiv protease inhibiting sulfonamides | Abbott Laboratories (US) | 2010-08-11 | — | — | EP | disclosed |
| US-7696226-B2 | HIV protease inhibiting compounds | ABBOTT LABORATORIES (US) | 2010-04-13 | — | — | US | disclosed |
| EP-1709037-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2006-10-11 | — | — | EP | disclosed |
| EP-1697348-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2006-09-06 | — | — | EP | disclosed |
| US-20050159469-A1 | HIV protease inhibiting compounds | ABBVIE INC. | 2005-07-21 | — | — | US | disclosed |
| WO-2005061450-A2 | HIV PROTEASE INHIBITING SULFONAMIDES | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005061487-A1 | HIV PROTEASE INHIBITING COMPOUNDS | ABBOTT LABORATORIES (US) | 2005-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023463-A1 | HIV PROTEASE INHIBITING COMPOUNDS | SERPINB1, HPN, DNPEP | HDAC6 1172/4885SMN1; SMN2 4444/4885USP2 707/4885 |
| US-20050159469-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | HDAC6 1172/4885SMN1; SMN2 4444/4885USP2 707/4885 |
| US-20140194349-A1 | HIV Protease Inhibiting Compounds | SERPINB1, HPN, DNPEP | HDAC6 1172/4885SMN1; SMN2 4444/4885USP2 707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.